Skip to main content
. Author manuscript; available in PMC: 2008 Feb 15.
Published in final edited form as: Clin Pharmacol Ther. 2007 May 9;83(1):52–60. doi: 10.1038/sj.clpt.6100221

Table 3.

HRR between PTGS1 and PTGS2 polymorphisms and risk of incident ischemic stroke or CHD events

Caucasian
African American
Polymorphism HRR 95% CI P-value HRR 95% CI P-value
Stroke
 G-1006A (PTGS1) G/A+A/A versus G/G G/A+A/A versus G/G
  Model 1a 1.78 1.08–2.92 0.024 1.46 0.88–2.40 0.137
  Model 2b 1.70 0.99–2.93 0.056 1.16 0.64–2.10 0.616
 G-765C (PTGS2) G/C+C/C versus G/G G/C+C/C versus G/G
  Model 1a 0.78 0.51–1.18 0.236 1.54 0.98–2.41 0.059
  Model 2b 0.79 0.50–1.25 0.314 1.76 1.05–2.94 0.031
CHD
 G-1006A (PTGS1) G/A+A/A versus G/G G/A+A/A versus G/G
  Model 1a 1.13 0.80–1.60 0.487 1.15 0.76–1.75 0.509
  Model 2c 1.28 0.87–1.89 0.206 1.25 0.77–2.04 0.367
 G-765C (PTGS2) G/C+C/C versus G/G G/C+C/C versus G/G
  Model 1a 1.01 0.79–1.29 0.929 1.00 0.70–1.41 0.991
  Model 2c 1.08 0.83–1.42 0.567 1.03 0.69–1.52 0.894

CI, confidence interval; HRR, hazard rate ratio.

a

Adjusted for age, gender, and study center.

b

Adjusted for age, gender, study center, current smoker, diabetes, and hypertension.

c

Adjusted for age, gender, study center, current smoker, diabetes, hypertension, high-density lipoprotein cholesterol, total cholesterol, and body mass index.